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Summary
An HLA-A2+ cytotoxic T lymphocyte (CTL) line restricted by HLAA2 in recognition of an
influenza B virus nucleoprotein (BNP) peptide uses the CD8 coreceptor in the recognition of
this viral peptide. Incubation of these CTL with BNP peptide in the absence of antigen-presenting
cells downmodulates CD8a and CD80 expression and reduces their ability to lyse target cells
without inducing self-lysis. CD8 downmodulation was dependent on peptide concentration,
time of exposure, and T cell receptor specificity. Another viral peptide from the influenza A
virus matrix protein interacting with HLAA2 had no effect on CD8 expression. Upon further
investigation, an anti-HLA class I monoclonal antibody (mAb), anti-HLA class II mAb, and
HLA alloantisera were found to downmodulate CD8a and CD8# expression and induce CTL
nonresponsiveness without causing degranulation. When CD8a and CD8a expression was
modulated by viral peptide or anti-HLA mAbs, other cell surface molecules were unchanged.
Finally, incubation ofperipheral blood lymphocytes with these anti-HLA mAbs induced no change
in CD8 expression on resting cells but did downmodulate it on mitogen-activated cells. These
results suggest that T cell recognition of the HLAA2-BNP peptide complex on neighboring
CTL may be the mechanism for CD8 downmodulation induced by the BNP viral peptide. This
mechanism may be important in clonal anergy.
Activation of T lymphocytes occurs when the TCR recog-
II nizes HLA molecules and antigen on APC (1). In
binding to this ligand, the TCR is assisted by CD8 or CD4
accessory molecules expressed on T lymphocytes (2, 3) . In
general, CD4 and CD8 molecules are expressed in a mutu-
ally exclusive manner on mature T cells and have therefore
been used to define two T cell subsets (4, 5). The majority
of CD8+ cells with cytotoxic function recognize antigen
with HLA class I molecules, whereas CD4+ cells with
helper function recognize antigen with HLA class II mole-
cules (6, 7) . In this T cell recognition, CD8 and CD4 mole-
cules are thought to both strengthen the interaction between
T cells and APC by binding to HLA molecules (8-10) and
assist in activation through their association with a tyrosine
protein kinase (11-13). When CD8 or CD4 expression is
blocked with specific mAbs, T cells can not be activated
(14, 15).
The importance of CD8 molecules in T cell responsive-
ness has also been established from studies usingcloned TCR
genes. When a transgene TCR restricted by H-2Db in its
specificity for fluorescein is expressed on CD8- cells, no lysis
of lymphoblast target cells occurs unless a cotransfected CD8
gene is expressed along with the transgene TCR (16). Male
mice carrying a transgene TCR specific for the HY male an-
tigen and restricted by the class I molecule, H-2Db, have pe-
ripheral T cells nonresponsive to the HY antigen (17). This
peripheral T cell tolerance is apparently brought about by
peripheral T cells expressing the transgene TCR on T cells
with low expression of CD8. Downmodulation ofCD8 mol-
ecules could explain why the transgene T cells have low CD8
expression, as downmodulation of IgM has been correlated
with B cell nonresponsiveness (18). CD8 molecules have been
found to be downmodulated on thymocytes incubated with
anti-CD3 or PMA and on alloreactive CTL treated with PMA
or alloantigen (19, 20), although neither the signal nor the
effect of this downmodulation on T cell responsiveness have
been determined.
In this study, a CTL line, from individual A.T, restricted
by HLAA2 and specific for a viral peptide from influenza
B nucleoprotein (BNP),' 82-94, (21) has been used. Direct
interaction of the viral peptide with these CTL was inves-
tigated since preincubation ofhelper T cells with their target
viral peptide or of HLA-A2 alloreactive CTL with an HLA-
A2 peptide has been reported to inhibit T cell responsiveness
(22, 23). CTL incubated with the BNP peptide downmodu-
late CD8a and CD80 expression and decrease their ability
'Abbreviation used in this paper . BNP, influenza B nucleoprotein.
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selves. The effect appears to be specific to CD8a andCD8a,
and not due to cocapping of several cell surface molecules,
sinceincubation ofCTLwith theBNP peptidedid not change
CD3, HLAA2, HLA-DR, or a2-microgloblin expression.
This effect is dependent on time of exposure to peptide, con-
centration of peptide, and TCR specificity, because another
viral peptide from the influenza A matrix protein that in-
teracts with HLA-A2 does not downmodulate CD8 expres-
sion on this CTL line. In determining how the viral peptide
downmodulated CD8, two anti-HLA mAbs and HLA al-
loantisera were identified that also downmodulatedCD8 ex-
pression. CTL incubated with anti-HLA-A2 (clone MA2.1)
or anti-HLADR (clone L243) downmodulated CD8a and
CD8a expression andlost responsiveness, without changing
expression of othercell surfacemolecules. CD8 downmodu-
lation by anti-HLA mAbs depends on mAb concentration,
presence of antibody aggregates, and time of exposure. Both
mAbs downmodulated CD8 on activated PBL without
affecting CD8 expression on restingPBL. Theseresults sug-
gest that crosslinking HLA molecules on activated T cells
downmodulates CD8expression, therebyinducing Tcell non-
responsiveness.
Materials and Methods
Cytotoxic T Lymphocytes.
￿
The A.T. CTL line grown from an
influenza B virus-specific polyclonal culture and has been shown
to be HLAA2 restricted andspecific forapeptide from theinfluenza
B virus nucleoprotein, 82-94, as described (21).
Cytotoxic TLymphocyte Assay.
￿
CTL killing wasquantitated by
a 5-h "Cr-release assay as described (24). Target cells were autol-
ogous EBVtransformed B lymphocytes labeled with sodium "Cr-
chromate (AmershamInternational, Amersham, UK) andincubated
for 1 h at 37°C with 100 ,Ag/ml viral peptide in RPMI with 10%
FCSor medium alone. Target cellswerewashed threetimesin RPMI
with 10% FCS before addition to the assay. OKT3 and MA2.1
hybridomacellsused as target cellswere radiolabeled,washed, and
addedto the CTL assay. CTLused as target cellswere labeled with
"Cr-chromate, incubated for 2 h with 100 ttg/ml viral peptide,
washed, and incubated for 5 h in a CTL assay. CTL prepared as
targets were viable, and the spontaneous release in the absence of
effectors was <20%. Where indicated in the text, CTL (106 cells/
ml) used as effectors were preincubated for 10 h with anti-HLA
mAb at 100 14g/ml in RPMI with 10% FCS, or preincubated for
2-10 h with 100,ug/ml viral peptide, washed, and added to the
CTL assay at the indicated killer to target (K/T) ratio. This incu-
bation had no effect on cell viability.
Antibodies, Purification, and Antibody Conjugates.
￿
Purified anti-
bodies were obtained from ascites as described (25) . Briefly, immu-
noglobulin was precipitated from ascites twice by 45% saturated
ammonium sulfate, resuspended in PBS with 0.1% NaN3, and
purified by gel filtration using G-200 superfine or by affinity chro-
matography using recombinant protein G. Purity was determined
by coomassie SDS-PAGE, and column fractions were pooled.
Purified mAbs were stored in PBS with 0.1% NaN3 at -70°C.
Aggregate formation was facilitated by storage at 4°C. Anti-aZ-
microglobulin (clone L368), FITC-conjugated anti-CD2, FITC-
conjugated anti-II*2R, PE-conjugated anti-CD3, andFITC-conjugated
anti-CD3 were gifts from Becton Dickinson Immunocytometry
Labs (Mountain View, CA). Other mAb clones used were anti-
CD8a (clone B941), anti-CD8a (mAb 597; reference 26), anti-
HLA-DR (clone L243), and anti-HLA-A2 (clones PA2.1 and
MA2.1). FITC was conjugated to purified mAb (2 mg/ml) at 100
legFITC per milligramof antibody overnight at 4°C, andpurified
over PD10 columns as described (27). HPLC profiles of purified
antibody were obtained on 100-Al mAb aliquots loaded at different
concentrations onto a Superose 12 column on FPLC system (Phar-
macia Fine Chemicals, Piscataway, NJ) run at 0.25 ml/min col-
lecting 250-,ul fractions monitored by UV absorption.
Immuwfluorescence
￿
CTL (2 x 105cells) and PBL (106 cells) were
used forimmunofluorescence staining. Cells were resuspended in
100 pl PBS with 0.10% NaN3 containing 5 lAg/ml PE-conjugated
or 20 lAg/ml (saturating concentrations) FITC-conjugated mAb.
Aftera15-min incubation at 4°C, cellswere washed andresuspended
in PBScontaining 1% paraformaldehyde. Cells were protected from
light and kept at 4°C until analysis by flow cytometry.
Flow Cytometry.
￿
Immunofluorescence data was detected on a
FACScan, whichdistributes thefluorescence intensity over afour-
decade log scale (Becton Dickinson Immunocytometry Systems).
Each immunofluorescence profile shownin thetext represents 5,000
live cells gated by forward-angle and 90° light scatter.
Results
TCell Nonresponsiveness by ViralPeptide andAnti-CD8.
￿
The
AT CTLline is specific for theinfluenzaBNPpeptide, 82-94,
restricted by HLAA2 (21). AT CTL are nonresponsive in
thepresence of anti-CD8 but not in the presence of another
mAb of identical isotype and concentration, demonstrating
therequirement of CD8 in recognition of the BNP peptide
(Fig. 1 A) . AT CTL are also less responsive to target cells
afterpreincubation with the BNP peptide, in the absence of
APC (Fig. 1 B). Because these CTL express HLAA2, the
decrease in responsiveness couldhave occurred from CTL lysis
ofneighboringCTL expressing HLAA2 with the BNP pep-
tide. However, AT CTL prepared as target cells were not
lysedby AT CTL (Fig. 1B). This observation wasnotunique
to the AT CTL line, as similar results were obtained with
another HLA-A2-restricted CD8+ CTL line, from indi-
vidualJ.M. specific for theinfluenza A virusmatrix peptide,
56-68 (28; Fig. 1 C). Thus, for these two CD8+ CTLlines,
a decrease in responsiveness was induced by direct interac-
tion with their viral peptide, by a route apparently distinct
from self-lysis. The ability of CTL to avoid lysis by them-
selves and by other CTL has been previously noted (29, 30).
CD8 Downmodulation by Viral Peptide. To determine
whether incubation of CTL with the viral peptide induced
changesin cell-surface glycoproteins, mAb binding to Tcell
antigens was examined. CTL were preincubated with 100
hg/ml BNPpeptideor with medium for 10 h, washed, and
then stainedwith FITC-conjugatedmAbs. CTL preincubated
with the BNPpeptide had downmodulated CD8a andCD8a
but not HLA-A2, a2-microglobulin or HLA-DR expression
(Fig. 2), suggesting that downmodulation was not due to
cocapping of several cell surface molecules. CTL were next
preincubated with either theBNPpeptide or matrix peptide
over a 10-h time period and examined for changes in CD8
and CD3 expression (Fig. 3) . Both the matrix peptide and
the BNP peptide bind HLAA2, but only the BNP peptide
is recognized by the AT CTL TCR (21, 28). Incubation
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with the BNP peptide downmodulated CD8 expression on
a significant fraction of CTL within the line. Incubation of
the AT CTL line with the matrix peptide had no effect on
CD8 expression (Fig. 3 A), and neither peptide altered CD3
expression during this time period (data not shown). Similar
results were obtained with theJ.M. CTL line in that incuba-
tion with the matrix peptide but not the BNP peptide down-
modulated CD8 expression (data not shown). CD8 down-
anti-CDSa anti-CD8p anti-HLA-DR
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Figure 1.
￿
Responsiveness of CTL to viral peptides. (A) A.T. CTL lysis of autologous EBVtransformed B lymphoblasts preincubated in 100,ug/ml
BNP peptide for 1 h in the presence of medium alone ("), 0.81 Ftg/ml IgGI anti-CD8 mAb (/), or 0.81 pg/ml IgG1 anti-HLA-DQ mAb (A).
(B) AT CTL lysis of autologous B lymphoblasts preincubated in 100 ug/ml BNP peptide for 1 h ("), lysis of the same targets after AT CTL (106
cells/ml) were first preincubated for 2 h in 100 Ag/ml BNP peptide followed by washing with centrifugation before addition to the CTL assay (A),
and lysis by AT CTL of s'Cr-labeled AT CTL preincubated for 2 h in 100 Ag/ml BNP peptide followed by washing with centrifugation before
addition to the CTL assay (N). KT refers to the ratio of CTL to target cells. (C) J.M. CTL lysis of autologous B lymphoblasts preincubated in 100
Ag/ml matrix peptide for 1 h ("), lysis of the same targets after J.M. CTL (106 cells/ml) were first preincubated for 2 h in 100 p,g/ml matrix as
above (A), and lysis by J.M. CTL of S1Cr-labeled J.M. CTL preincubated for 2 h in 100 Rg/ml matrix peptide as above (/).
modulation depended on the BNP peptide concentration (Fig.
3 B), which was most effective at 100 Ag/ml. The BNP pep-
tide is insoluble above 100 p,g/ml, so higher concentrations
could not be tested. Because downmodulation was peptide
specific suggests that it might be due to CTL recognition
of the HLA-peptide complex on neighboring CTL. That
100% ofthe cells were not downmodulated probably reflects
the different TCR affinities within the CTL line. If the effect
anti-MLA-A2
a r
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Figure 2.
￿
Expression of cell surface molecules on AT CTL preincubated with and without the BNP viral peptide. Antigen expression on CTL
preincubated in medium alone (top) and in 100 ug/ml BNP peptide (bottom) for 10 h at 37°C. Cell surface molecules were detected by the FITC-
conjugated mAb indicated at the bottom of each column.L
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is due to T cell recognition of HLA-peptide complex, cells
with downmodulated CD8 coreceptor will be impaired in
theirability to recognize HLApeptide complexes on remaining
T cells.
Nonresponsiveness and CD8 Downmodulation by Anti-HLA
Antibody. In the process of determining whether peptide
was interacting with HLA-A2, incubation ofCTL with 100
hg/ml MA2.1, an anti-HLAA2 mAb interacting with residues
62-66 in the a1 domain of HLAA2 (31, 32), was found to
downmodulate CD8ot and CD80 without changing CD3,
CD2, IIr2R, or /32-microglobulin expression (Fig. 4 A).
Another anti-HLAA2 mAb, PA2.1, which reacts with HLA-
A2 residue 107 outside the TCR site (32, 33), had no effect
on CD8 expression (data not shown). When CTL were in-
cubated for 10 h with 100 hg/ml MA2.1 or PA2.1, and then
tested in a 5-h CTL assay, cells incubated with MA2.1 but
not PA2.1 were nonresponsive (Fig. 4 B). This downmodu-
lation by anti-HLAA2 mAb (clone MA2.1) depended both
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Figure 3.
￿
Kinetics, specificity, and
peptide concentration ofCD8 down-
modulation. (A) Expression ofCD8a
detected by FITC-conjugated anti-
C138 mAb binding to A.T. CTL after
preincubation of CTL (106 cells/ml)
with 100 ttg/ml BNP peptide (left)
and with 100 ug/ml matrix peptide
(right). Incubation with viral peptides
was done over a 10-h time period in-
dicated at the left. (B) Expressionof
CD8cx detected by FITC-conjugated
anti-CD8 binding to A.T. CTL prein-
cubated for 10 h in the concentration
ofBNP peptide indicated at the left.
on the concentration of antibody (Fig. 4 C) and time of ex-
posure (data not shown). This anti-HLAA2 mAb also down-
modulated CD8 expression and induced nonresponsiveness
of a HLA-A2-positive HLA-B27-restricted CTL line to in-
fluenza A virus nucleoprotein peptide, 380-392 (34; data not
shown). Hence, the effect of the mAb was not limited to
the restricting HLA molecule.
To determine whether other HLA molecules expressed on
A.T. CTL (HLA type: HLAA2,11; B54,60; Cwl; DR4,12;
DQw3) could alter CD8 expression, HLA alloantisera reacting
with these molecules were tested for their effect on CD8 ex-
pression. By testing panels of antisera with binding activity
to AT CTL, mono-specific serum to HLAA2, HLA-All,
HLACwl, HLADR12, and HLADQ3, and dispecificserum
to HLA-B40/60, were identified that had a strong to moderate
effect on CD8 expression (Fig. 5). CTL incubated with serum
specific for HLAA1, A24, A32, B8, B27, or Cw3 had no
effect on CD8 expression, ruling out effects due to Fc binding.N
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Effect ofanti-HLA-A2 on CD8 expression and CTL respon-
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preincubated in medium and in 100 wg/ml anti-HLA-A2 (clone MA2.1)
for 10 h at 37°C followed by washing with centrifugation. Cell surface
molecules were detected by the FITC-conjugated mAb indicated at the
bottom ofeach column. (B) AT CTL lysis ofautologous B lymphoblasts
preincubated in 100 Ag/ml BNP peptide (0), lysis of the same target cells
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O). (C) CD8ot expression detectedby FITC-conjugated anti-CD8 binding
to A.T. CTL (106 cells/ml) preincubated for 10 h with the concentration
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CD8 expression on AT CTL incubated with HLA alloantisera. FITC-conjugated anti-CD8 mAb binding to A.T. CTL incubated (106
cells/ml) for 10 h in 50% (vol/vol) of alloantisera containing the specificity indicated at the bottom of each picture.
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Figure 6.
￿
Effect of anti-HLA-DR mAb on CD8 expression and CTL responsiveness. (A) CD8 expression on AT CTL preincubated (106 cells/ml)
in medium and in 100 /tg/mI anti-HLA-DR (clone L243). (B) AT CTL lysis of autologous B lymphoblasts preincubated in 10014g/ml BNP peptide
("), lysis of the same targets after CTL were preincubated for 10 h at 37°C in 100 gg/ml of anti-HLA-DR (clone L243; O), and lysis by AT CTL
of autologous B lymphoblasts without peptide (0). (C) AT CTL lysis of 51Cr-labeled OKT3 hybridoma cells and MA2.1 hybridoma cells (O), and
lysis of the same target cells after AT CTL were preincubated for 10 h with 100 FAg/mI anti-HLADR (").
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to downmodulate CD8a and CD80 expression after 10 h
ofincubation with AT CTL, too (Fig. 6). Changes in CD3,
CD2, IIr2R, and a2-microglobulin expression were equally
undetectable, as in Fig. 4 (data not shown). This downmodu-
lation was complete using a 100 wg/ml ofanti-HLADR mAb
but also depended on antibody concentration (data not shown;
see Fig. 4 B). When these cells were tested in a CTL assay
after 10 h of incubation with anti-HLADR, they were un-
responsive to peptide on APC but not degranulated, because
they could still lyse OKT3 hybridoma cells (Fig. 6). Thus,
both anti-HLA class I and class II mAbs induced nonrespon-
siveness of CTL and downmodulated CD8 expression. The
degree of these effects depended on antibody concentration,
time of exposure, and the presence of antibody aggregates.
Aggregates of mAbs.
￿
When anti-HLA mAbs are cross-
linked they are better at inhibiting mitogen-induced prolifer-
ation of PBL (35) . In this study, the presence of antibody
aggregates also correlated with an increased capacity of a mAb
to downmodulate CD8. mAbs were purified from ascites by
gel filtration and checked by SDS-PAGE for purity, as de-
scribed (25). Nevertheless, different mAb aliquots showed
variability in downmodulating CD8 expression. Adding to
this anomaly was the observation that CD8 expression was
only completely downmodulated using 100 [tg/ml of anti-
body, a concentration way above saturation (see Fig. 4 C).
FPLC examination of 17 samples of purified anti-HLA-DR
and anti-HLAA2 mAbs revealed that monomers, which eluted
between fractions 45 and 50, under the FPLC conditions used,
never had any activity on CD8 expression, at any concentra-
tion, and were the only protein peaks present immediately
after purification of antibody from ascites (data not shown).
In contrast, mAb aliquots that downmodulated CD8 had
additional peaks of protein in fractions 31 and 41, as well
as the monomer peak in fractions 45-50 (Fig. 7). These frac-
tions of higher molecular weight stained HLA-A2-positive
cells, as did the monomer peak, but all the functional ac-
.16
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.12-
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.04
.021
4447
tracdom
Figure 7. Aggregates of mAb
downmodulate CD8. HPLC profile
of a 100-,1 aliquot of anti-HLA-A2
(clone MA2.1) loaded at 6 mg/ml
onto a Superose 12 column on a FPLC
system (Pharmacia Fine Chemicals)
run at 0.25 ml/min collecting 250-Ftl
fractions. The left axis indicates the
UV monitor sensitivity meter, reading
ODD, set at 0.2 x 1. The bottom
axis indicates relevant positions ofthe
fractions collected.
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tivity of downmodulating CD8 was mainly in fraction 31
(active at 4 lAg/ml), with partial activity in fraction 41. The
activity in these peaks could be absorbed out by HLAA2
transfectants (data not shown). These results suggest that the
fractions of higher molecular weight most likely represent
aggregated mAbs, which are biologically active at concen-
trations below that of saturation. The aggregation may facili-
tate crosslinking of HLA molecules.
Anti-HLA mAb Does Not Block Anti-CD8 Binding.
￿
Be-
cause CD8 molecules have been reported to coassociate with
HLAA2 molecules (36), the ability ofanti-HLAA2 to block
anti-CD8 binding was examined. Incubation of A.T. CTL
with 100 p./ml anti-HLAA2 for 15 min at 4°C (mAb ac-
tivity shown in Fig. 4 B) completelyblocked anti-HLA-A2
mAb binding, while anti-CD8 mAb binding was not affected
at all (data not shown). As well, the anti-HLA-DR mAb
did not block anti-CD8 mAb binding at 4°C under iden-
tical conditions (data not shown). Furthermore, when resting
PBL were incubated for 10 h at 37°C with 100 p,g/ml of
anti-HLA-A2 mAb, no CD8 modulation was detected un-
less cells were first activated by mitogen (Fig. 8). Again, similar
results were obtained with the anti-HLA-DR mAb. These
results suggest the effect on CD8 expression by HLAspecific
mAbs is not due to simple cell surface blocking of CD8 ex-
pression.
Discussion
In this study, CTL preincubated with their specific viral
peptide in the absence of APC become nonresponsive. This
decrease in responsiveness could be demonstrated without any
detection of self-lysis. When the cell surface of CTL prein-
cubated with viral peptide was examined, both CD8a and
CD80 were downmodulated without changes in CD3, HLA
A2, HLA-DR, or a2-microglobulin expression. This sug-
v
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Activated PBL
Figure 8. Anti-HLA-A2 does not block anti-CD8 binding. FITC-
conjugated anti-CD8 mAb binding to A.T. PBL preincubated in medium
or in 100,ug/ml anti-HLA-A2 (MA2.1) for 10h at 37°C and to A.T. PBMC
activated for 4 d with 5 Wg/ml tuberculosis purified protein derivative fol-
lowed by preincubation in medium or in 100Wg/ml anti-HLA-A2 (MA2.1)
for 10 h at 37°C.
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anti CD8 "'gests that downmodulation was specific to CD8 and not due
to cocapping of several cell surface molecules. The degree of
nonresponsiveness and CD8 downmodulation varied between
experiments. For example, when CTL were incubated for 10 h
with peptide and put in a 5-h CTL assay, there was no lysis
of target cells (data not shown). Although, in two separate
experiments shown in Fig. 2 and 3, CTL incubated for 10 h
with the BNP peptide still expressed some CD8; it was never
completelydownmodulated afterCTL were incubated in the
BNP peptide. The difference between CTL responsiveness
and CD8 expression may reflect the TCR affinities' presence
within the CTL line. Partial CD8 downmodulation might
be expected if caused by T cell recognition of the HLAA2-
peptide complex, as cells with downmodulated CD8 co-
receptor would be impaired in their ability to recognize
peptide-HLAA2 complexes on remaining T cells. However,
it is also possible that the difference between nonresponsive-
ness and CD8 expression might be accounted for by loss of
other cell surface molecules not examined in this study. A
change in TCR expression could have a profound effect on
CTL responsiveness. Expression of CD3 molecules usually
taken as an indication of TCR expression was not downmodu-
lated by any of the procedures. However, the lack of TCR
mAbs reacting with the TCRs on these CTL prohibited ex-
amining TCR expression directly. TCRs might be lost from
the cell surface with similar or different kinetics from CD8
expression. However, because these CTL require the CD8
coreceptor in recognition of the BNP peptide (Fig. 1), im-
pairment ofCD8 expression would be enough to abolish re-
sponsiveness of these CTL.
Downmodulation of CD8 expression was specifically medi-
ated by the BNP viral peptide. The influenza A virus matrix
peptide, which binds HLAA2 (29), had no effect on CD8
expression on AT CTL (Fig. 3). That both peptides bind HLA
A2 but only the BNP downmodulated CD8 expression im-
plies downmodulation occurred from the BNP peptide binding
directly to the TCR or from T cell recognition of the BNP
peptide in HLAA2 molecules on the CTL. In the process
of sorting out these possibilities, an anti-HLAA2 mAb was
found to have an similar effect to the BNP peptide. It both
downmodulated CD8a and CD8fl expression and made the
CTL nonresponsive. An anti-HLADR mAb also downmodu-
lated CD8a and CD8fl expression and made the CTL non-
responsive. In this latter case, when CTL were nonrespon-
sive, they were still able to kill OKT3 (anti-CD3) hybridoma
cells but not MA2.1 (anti-HLA-A2) hybridoma cells, sug-
gesting that CTL treated with anti-HLA mAbs might be
nonresponsive because ofloss of CD8 expression and not from
some nonspecific degranulation of the CTL. That incuba-
tion of the CTL with either the viral peptide or with anti-
HLA mAb selectively altered CD8 expression without
changing expression of other cell surface molecules (Figs. 2,
4, and 6) suggests CD8 downmodulation obtained with the
viralpeptide might be due to an interaction involving HLA-
A2. That such an effect does not occurbecause of direct pep-
tide binding to HLA is supported by the lack of an effect
obtained with the matrix peptide in Fig. 3. Furthermore,
that the effect with anti-HLA mAbs requires aggregated an-
tibody suggests again that HLA molecules may not be simply
bound by anti-HLA antibodies but crosslinked. Hence, the
downmodulation of CD8 resulting from incubation of CTL
with the BNP viral peptide may be due to CTL recognition
of the BNP peptide in HLAA2 molecules on neighboring
CTL. This T cell recognition may crosslink HLA molecules.
How crosslinking HLA molecules actually brings about
changes in CD8 cell surface expression remains to be deter-
mined. Certainly, it seems clear that interactions between dis-
tinct cell surface glycoproteins can be a means for altering
cell function. But whether these interactions occur via the
cell surface or through the cytoplasmic domain has yet to
be determined in the cases where TCR crosslinking increases
adhesiveness ofLFA1, where binding to TNF receptor down-
modulates CSF receptors, or where binding to the ID4R alters
expression of II,2R (37-39). Cell surface interactions between
HLA molecules and CD8 molecules cannot be formally ruled
out since HLA class I molecules have been shown to bind
CD8 molecules (9) and associate intracellularly with CD8
molecules (36). However, HLA class II molecules have never
been shown to bind CD8 molecules, and neither HLA class
I nor class II molecules have been shown to bind CD8a chains
A cell surface interaction between HLA and CD8 is unlikely
therefore to explain the CD8 downmodulation.
Internalization of CD8 could be a possible mechanism to
account for downmodulation of CD8. But it is controversial
as to whether CD8 molecules are internalized afterphosphory-
lation; two processes that are usually associated (40, 41). This
stems from the observation that CD8 phosphorylation on
thymocytes and peripheral lymphocytes is not accompanied
by internalization (11). However, both CD8 phosphoryla-
tion and the disappearance ofCD8 expression occur on CTL
treated with PMA (20). On the other hand, CD8 molecules
have been found in the serum of individuals with extensive
viralinfections and in the culture medium4 PHAactivated
lymphocytes (42). This might be taken as evidence for a mech-
anism of CD8 shedding. In the case of the mouse homing
receptor, it is shed after proteolytic cleavage from the cell
surface (43) . Thus, such a mechanism might also operate for
downmodulation of CD8 molecules.
A number of reports have shown that anti-HLA class I
and class II mAbs inhibit mitogen-induced T cell prolifera-
tion (44-47) . In these cases, the anti-HLA antibodies may
be mimicking T cell recognition as they apparently do in
our study. The type of T cell interaction whereby a CD8
T cell recognizes HLA class I-peptide complexes on neigh-
boring T cells might account for one mechanism of immu-
noregulation. Certainly, the notion that CD8+ T lympho-
cytes can immunoregulate peripheral T cell responses has
existed for 20 yr since first suggested by Gershon and Kondo
(48), but the mechanism for this type ofimmunoregulation
has proved elusive.
In conclusion, downmodulation of cell surface molecules
could be a mechanism for immunoregulation by inducing
nonresponsiveness ofimmune cells. Downmodulation of IgM
has been reported to induce tolerance to a self antigen in pe-
ripheral B cells(18), and in the case ofperipheral T cell toler-
ance, reduced CD8 expression was found (17), possibly
228
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here suggestthat when cytotoxicT lymphocytes become non-
responsive, this is accompaniedby downmodulation of CD8
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